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‘‘La Sapienza’’, Rome, ItalyCholangiocytes, which line the biliary epithelium, are hormone-
responsive and responsible for the modiﬁcation of canalicular
bile before reaching the duodenum. Cholangiocytes are the target
cells in cholangiopathies such as primary biliary cirrhosis (PBC)
and primary sclerosing cholangitis (PSC) that are characterized
by cholangiocyte proliferation/loss [1]. The biliary epithelium is
morphologically and functionally heterogeneous and is lined by
small (<15 lm in diameter) and large (>15 lm in diameter) cho-
langiocytes lining small and large bile ducts, respectively [2].
Cholangiocyte responses are regulated by both Ca2+- and cAMP-
dependent signaling [2–5].
Histamine is a biogenic amine that is mostly recognized for its
role in allergy-related diseases. After histamine is formed from the
decarboxylation of the amino acid histidine, by histidine decar-
boxylase (HDC), it is rapidly stored or degraded. Histamine exerts
its effects through four G-protein coupled receptors (GPCRs),
H1–H4 histamine receptors (HRs) [6]. Activation/inhibition of
HRs triggers downstream signaling pathways to elicit cellular
responses such as proliferation, apoptosis, and differentiation.
It has been shown that histamine plays a critical role in liver
repair and regeneration. The H1 histamine receptor affects
gamma-glutamyltransferase (c-GT) levels during liver regenera-
tion after partial hepatectomy in rats [7]. Blocking H1HR
increased serum c-GT activity, whereas inhibition of H2HR did
not have a signiﬁcant effect in this model [7]. Histamine, via
the H4HR, protects against ischemia/reperfusion liver injury by
decreasing cytokine release [8]. These studies demonstrate the
varying role of histamine in liver injury and the potential beneﬁts
of histamine during the progression of liver damage.
Our group has demonstrated that histamine, via the four his-
tamine receptors, H1–H4HRs, induces a differential response in
cholangiocyte proliferation via diverse signaling pathways as
shown in Fig. 1 [4,5,9,10]. We have found that all HRs are present
on cholangiocytes and that these receptors are both inhibitory
(H3–H4HRs) and stimulatory (H1–H2HRs) during cholangiocyte
proliferation [4,5,9,10].Journal of Hepatology 20
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Open access under CC BY-NC-ND license.In a rodent model of cholangiocyte proliferation induced by
bile duct ligation (BDL), we have demonstrated that stimulation
of the inhibitory H3HR by an H3HR agonist decreases BDL-
induced cholangiocyte hyperplasia [4]. Activation of H3HR (that
couples to Gai) inhibits cAMP signaling with a subsequent
decrease in the phosphorylation of ERK1/2 and the transcription
factor, Elk1 [4]. Inhibition of cholangiocyte proliferation may be a
useful therapy for treatment of cholangiopathies characterized by
increased biliary hyperplasia (Fig. 1, top panel).
We also found that histamine, via H1HR (coupled to Gaq)
regulates small cholangiocyte proliferation without inducing
any effects in large cholangiocytes [5]. Using cultured mouse
cholangiocytes, we found that stimulation of H1HR increases
the proliferation of small (but not large) cholangiocytes via
activation of IP3/Ca2+/PKC/CaMKI/CREB-dependent pathway as
shown in Fig. 1, top panel [5].
The H3HR signals either via Gai (inhibition of cAMP) or Gao
(activation of Ca2+). Using a speciﬁc agonist for the H3HR, we
evaluated the effects of this agonist on cholangiocarcinoma
growth [9]. We demonstrated that activation of H3HR decreases
cholangiocarcinoma growth both in vitro and in vivo [9]. Surpris-
ingly, the effects by RAMH were mediated not by inhibition of
cAMP signaling, but by activation of the IP3/Ca2+/PKCa [9]. We
demonstrated that activation of PKCa led to decrease ERK1/2
phosphorylation and subsequent decreased biliary proliferation
as shown in Fig. 1, bottom panel.
In a separate study, we have evaluated the speciﬁc role of the
H4HR agonist, clobenpropit, on cholangiocarcinoma growth and
metastatic potential [10]. We demonstrated that by activation
of H4HR cholangiocarcinoma growth decreases (both in vitro
and in a xenograft tumor model) and epithelial–mesenchymal
transition is also inhibited. Our ﬁndings suggest that the activa-
tion of H4HR decreases the expression of extracellular matrix
degrading enzymes, matrix metalloproteinases preserving the
extracellular matrix and making tumor spreading more difﬁcult
[10]. Further, we found that H4HR allows cholangiocarcinoma
cells to maintain more of an epithelial cell-type phenotype by
preserving the expression of numerous hepatobiliary markers
including the cytokeratins, CK-7, -8, and -19. The actions of
H4HR were mediated by activation of a Ca2+/PKC-dependent
pathway similar to what we found using an agonist for H3HR
as depicted in Fig. 1, bottom panel [10].
Studies have shown that cholangiocytes (that are normally)
dormant, proliferate after BDL, a model that mimics human12 vol. 56 j 1204–1206
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Fig. 1. Top panel: In normal and during cholestatic injury, histamine receptors are found in small and large cholangiocyte populations. Expression levels of HRs have
not been found to have a signiﬁcant impact on cholangiocyte response, however, activation of speciﬁc histamine receptors results in differential downstream signaling.
H1HR couples mainly to Gaq that mobilizes the IP3/Ca2+/PKC-dependent pathway with subsequent increased cholangiocyte proliferation. Our data suggests that the effects
of H1HR are predominantly found in small cholangiocytes, as this population is known to signal via Ca2+-dependent pathways. H2HR activates cAMP-dependent
mechanisms that increase cholangiocyte proliferation. Large cholangiocyte proliferation is regulated primarily by cAMP activation and our data has supported this concept.
The H3 and H4HRs are predominantly inhibitory receptors that are able to either inhibit cAMP synthesis or activate Ca2+/PLC-dependent pathways. The result of H3 or H4
activation is decreased cholangiocyte proliferation that we believe occurs mostly in large cholangiocytes. Bottom panel: During cholangiocarcinoma, histamine and the
enzyme responsible for histamine synthesis, histidine decarboxylase (HDC), are upregulated thus activating speciﬁc histamine receptors. We have found that after
activation of the inhibitory receptors, H3 and H4, cholangiocarcinoma growth decreases. H3HR activates Ca2+/PKCa-dependent signaling that decreases cholangiocar-
cinoma growth, whereas H4HR signals via Ca2+-dependent mechanisms to decrease EMT, ECM degradation and tumor spreading. We suggest that inhibition of the
stimulatory H1 or H2 HR will result in decreased cholangiocarcinoma growth presumably by inhibition of Ca2+-dependent or cAMP-dependent pathways. ECM,
extracellular matrix; EMT, epithelial mesenchymal transition; HA, histamine; HDC, histidine decarboxylase; HR, histamine receptors; MMPs, matrix metalloproteins.
JOURNAL OF HEPATOLOGYcholestatic liver disease [3,4]. While these studies above
document the role of histamine and HRs during diseased states,
preliminary data show that normal cholangiocytes can be acti-
vated to proliferate via histamine and two stimulatory histamineJournal of Hepatology 2012receptors, H1HR and H2HR. We demonstrated that histamine
increases normal cholangiocyte proliferation via activation of
both Ca2+- and cAMP-dependent pathways. When elucidating
the speciﬁc histamine receptors, we discovered thatvol. 56 j 1204–1206 1205
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H1HR increases normal cholangiocyte growth via a Ca2+/PKCa-
dependent pathway, whereas H2HR activates cAMP synthesis to
increase normal cholangiocyte proliferation. We have data dem-
onstrating that H1HR-induced cholangiocyte proliferation occurs
in small cholangiocytes (regulated by Ca2+-dependent signaling)
whereas H2HR-induced cholangiocyte proliferation exists in large
cholangiocytes that signal via cAMP activation.
Overall, these ﬁndings are important in understanding the
differential response induced by histamine that may regulate
cholangiocyte proliferation during the progression of cholangiop-
athies or liver regeneration. Modulation of H1–H4HRsmay be key
for themanagement of the balance between biliary growth/loss in
cholangiopathies.
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